OMNIlife science evaluating active spacer robotic tissue balancing device — 3 insights

OMNIlife science began a clinical evaluation of its OMNIBotics Active Spacer robotic tissue balancing device at three U.S.-based sites.

Here's what you should know:

1. The FDA awarded the device 510(k) clearance in September.

2. The device is a quantitative tool to manage the soft tissue envelope with real-time feedback. Surgeons can use the device along with the OMNIBotics system to customize total knee replacement procedures, in terms of a skeletal and soft tissue perspective.

3. OMNIlife science is hoping the device helps patients reach optimal soft tissue balancing. Studies indicate a significant amount of patients are not fully satisfied with their TKR operation because of suboptimal soft tissue balancing.

Jeffrey Lawrence, MD, of Viroqua, Wis., said in a release, "I believe that the active space technology is the tool we have been looking for to create even better predictability and reproducibility for knee replacement surgery. I'm very excited to offer this system to my patients."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast